Health Catalyst (NASDAQ:HCAT – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $16.00 price objective on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 53.70% from the company’s previous close.
Separately, Canaccord Genuity Group cut their price target on Health Catalyst from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, August 29th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.55.
Health Catalyst Price Performance
Health Catalyst (NASDAQ:HCAT – Get Free Report) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. The firm had revenue of $73.21 million for the quarter, compared to the consensus estimate of $72.67 million. Health Catalyst had a negative return on equity of 16.49% and a negative net margin of 51.76%. On average, analysts predict that Health Catalyst will post -0.95 EPS for the current year.
Insider Activity at Health Catalyst
In related news, CAO Jason Alger sold 2,197 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $11.65, for a total value of $25,595.05. Following the completion of the sale, the chief accounting officer now directly owns 56,942 shares in the company, valued at $663,374.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 5,270 shares of company stock worth $60,828 over the last three months. Company insiders own 2.70% of the company’s stock.
Institutional Trading of Health Catalyst
A number of institutional investors and hedge funds have recently bought and sold shares of HCAT. Virginia Retirement Systems ET AL acquired a new stake in Health Catalyst during the 2nd quarter worth about $456,000. California State Teachers Retirement System grew its holdings in Health Catalyst by 6.3% during the 2nd quarter. California State Teachers Retirement System now owns 67,666 shares of the company’s stock worth $846,000 after acquiring an additional 3,984 shares during the period. Osaic Holdings Inc. grew its holdings in Health Catalyst by 88.7% during the 2nd quarter. Osaic Holdings Inc. now owns 7,339 shares of the company’s stock worth $92,000 after acquiring an additional 3,449 shares during the period. Wells Fargo & Company MN grew its holdings in Health Catalyst by 121.0% during the 2nd quarter. Wells Fargo & Company MN now owns 23,049 shares of the company’s stock worth $288,000 after acquiring an additional 12,619 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Health Catalyst during the 2nd quarter worth about $188,000. 86.63% of the stock is currently owned by institutional investors and hedge funds.
Health Catalyst Company Profile
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company offers data operating system data platform for analytics, and application development and interoperability that provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications designed to analyze the problems faced across clinical and quality, population health, and financial and operational use cases.
- Five stocks we like better than Health Catalyst
- Compound Interest and Why It Matters When Investing
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Reasons Price Weakness Is a Buying Opportunity For Lennar
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Name A Better Trio Than These Underrated High Potential Stocks
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.